Tag: Canntab Therapeutics

Canntab Files Application to Become Licensed Producer

MotherlodeTV
canntab, c.pill, cannabis

Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company“) a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “License“), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility. read more

Canntab Therapeutics: Cannabis in a Hard Pill

JayCurrie
C.PILL, Canntab Therapeutics, , cannabis

Jeff Renwick and Richard Goldstein (l&r above) have been working together on the generic side of the pharmaceutical business for a decade. Developing drugs and drug delivery systems. Renwick has a total of 25 years in pharma and Goldstein was an investment banker. Their private company had two generic drugs in the pipeline and a good deal of work on extended release formulations. read more

Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

MotherlodeTV
canntab, c.pill, cannabis
info

Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) (“Canntab” or the “Company“), today announced the completion of a non-binding Letter of Intent (the “LOI“) with NewCanna S.A.S of Bogota, Colombia (“NewCanna“) for the establishment of a significant bi-lateral relationship for the sale & distribution of Canntab’s products. The territory applicable to the agreement is the countries of Colombia, Chile, Paraguay and Spain, (collectively, the “Territory“). The agreement will grant NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab’s know-how and patents in the Territory only. read more

FSD Pharma Receives First Delivery of Cantabb Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets Per Day

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab  Therapeutics Limited (CSE:PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment. read more

Canntab Sets New All-Time High Trading Prices and Volume

MotherlodeTV
canntab, c.pill, cannabis
info

Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company“), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company’s common shares (“Common Shares“) yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the “CSE“). These numbers exceed the Company’s previous all-time highs by 39.2% and 15.6%, which were also set earlier this week. In addition, the Company traded an aggregate of 1,583,326 Common Shares yesterday at a total dollar value of $2.06M, which constitutes its all-time high daily volume and exceeds the Company’s previous highs, set on the Company’s opening day of trading on April 20, 2018. read more